@xconomy.com 4 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 7 months ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com 8 months ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com 9 months ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com 10 months ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 1 year ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com 1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 1 year ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com 1 year ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com 1 year ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com 1 year ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com 1 year ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com 1 year ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com 1 year ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com 1 year ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com 2 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”